🇺🇸 FDA

Intelligence · Patent portfolio

United Therapeutics Europe Patents

Full USPTO pharma patent portfolio for United Therapeutics Europe — grant dates, expiration, and drug cross-links.

Patents
3,720
Expiring ≤24m
234

Quick answer

United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months — use filters for patent-cliff planning.

Page 20 of 78

  1. US 10507187

    Regenerative tissue grafts and methods of making same

    Expires Mon Dec 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10508106

    Bicyclic BET bromodomain inhibitors and uses thereof

    Expires Mon Dec 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10507211

    Treatment for hereditary neuropathy with liability to pressure palsies (HNPP)

    Expires Mon Dec 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10500238

    Use of gram negative species to treat atopic dermatitis

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10500262

    Synthetic antigen constructs against Campylobacter jejuni

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10500269

    Human rotavirus vaccine strains and diagnostics

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10501428

    Thymoquinone derivatives for treatment of cancer

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10501528

    Immunoglobulin single variable domain antibody against RSV prefusion F protein

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10501507

    Griffithsin mutants

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10500264

    Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10500261

    Synthetic antigen constructs against campylobacter jejuni

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10501504

    Adhesin as immunogen against enterotoxigenic Escherichia coli

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10494683

    Nitrate- and nitrite-reducing probiotic feed additive

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10493087

    Sialylation-increasing therapies for diseases associated with oxidative stress

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10494435

    Human monoclonal antibodies specific for CD22

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10494327

    Controlled release pharmaceutical formulations

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10488417

    Compounds for use as imaging agents

    Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10485771

    Methods of regulating cannabinoid receptor activity-related disorders and diseases

    Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10487076

    Compositions and methods for treating diseases and conditions

    Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10485879

    Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues

    Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10485792

    Sustained release delivery systems for the prevention and treatment of head and neck cancers

    Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10480031

    Method for generating Retinal Pigment Epithelium (RPE) cells from Induced Pluripotent Stem Cells (IPSCs)

    Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10478435

    Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury

    Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10478410

    Process to prepare treprostinil, the active ingredient in Remodulin®

    Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10478487

    Foot-and-mouth disease vaccine

    Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10478415

    Ketone bodies to protect tissues from damage by ionizing radiation

    Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10472412

    Bispecific multivalent fusion proteins

    Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10471142

    Combination therapy using immunoglobulin and C1-Inhibitor

    Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10471061

    Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders

    Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10464970

    Compounds that bind to human immunodeficiency virus rev response element

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10463733

    Ultra-stable protein ionic liquids

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10456404

    Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods

    Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10456461

    Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus

    Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10449170

    Compositions for diagnosis and treatment of type 2 diabetes

    Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10450364

    Hyperimmunized egg product for treatment of necrotic enteritis in poultry

    Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10450372

    Anti-thyroglobulin T cell receptors

    Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10450371

    Monoclonal antibody and antigens for diagnosing and treating lung disease and injury

    Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10449231

    Compositions and methods for dengue virus chimeric constructs in vaccines

    Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10449171

    Compositions and methods for diagnosis and treatment of metabolic syndrome

    Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10441642

    Immunogenic compositions and vaccines for preventing or treating filarial disease

    Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10443073

    Sin Nombre virus full-length M segment-based DNA vaccines

    Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10434188

    Hyaluronic acid binding domain-growth factor fusion protein cDNAs and fusion proteins for cartilage matrix preservation and repair

    Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10435461

    Therapy for filovirus infection

    Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10434116

    Methods of treating coronavirus infection

    Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10435695

    Fusion protein comprising Gaussia luciferase, translation interrupter sequence, and interferon amino acid sequences

    Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10434174

    Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells

    Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10434167

    Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin

    Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10428314

    Human ebola virus species and compositions and methods thereof

    Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does United Therapeutics Europe have?

3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do United Therapeutics Europe patents expire?

234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.